For Healthcare Providers: A Dengue Vaccine Can Protect Your Patients
A Dengue Vaccine
Dengvaxia is the only dengue vaccine approved by the U.S. Food and Drug Administration and recommended for routine use by the Advisory Committee on Immunization Practices. It is made by Sanofi Pasteur. The vaccine prevents dengue caused by all four dengue virus serotypes.
Dengvaxia will be available starting in 2022 for use in children and adolescents 9–16 years old who have laboratory-confirmed previous dengue virus infection and are living in an area where dengue is endemic (occurs frequently or continuously). Dengue-endemic areas include the U.S. territories of American Samoa, Puerto Rico, and the U.S. Virgin Islands, and freely associated states, including the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau.
The vaccine is a tetravalent, live-attenuated dengue vaccine. It was constructed using recombinant DNA technology and replaces several genetic sequences in a yellow fever vaccine virus genome with the homologous sequences from the four dengue virus serotypes.